Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
ABEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.05 - $8.87
Previous CloseN/A
Volume71.38K
Average Volume (3M)303.80K
Market Cap
$237.35M
Enterprise Value$216.95M
Total Cash (Recent Filing)$18.75M
Total Debt (Recent Filing)$30.00M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 24, 2025EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding43,471,030
10 Day Avg. Volume380,700
30 Day Avg. Volume303,802
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)62.60
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit114.48
Enterprise Value/Ebitda-3.39
Forecast
1Y Price Target
$15.50Price Target Upside177.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Abeona Therapeutics News
PremiumCompany Announcements
Abeona Therapeutics Reports Q3 2024 Financial Highlights---
Bulls Say, Bears Say
Bulls Say
Market CompetitionThe efficacy and long-term durability of prademagene zamikeracel, along with the high list price of a competing product, should enable Abeona to outcompete Filsuvez in the RDEB population.
Regulatory ApprovalThe FDA has accepted for review the Biologics License Application (BLA) seeking accelerated approval for ABO-102 gene therapy as a treatment for patients with Sanfilippo syndrome type A.
Bears Say
Regulatory ChallengesThe CRL for pz-cel only raised CMC-related issues, with no safety or efficacy concerns, boosting confidence in its resolution.
---
Ownership Overview
7.46% Insiders
5.57% Mutual Funds
50.61% Other Institutional Investors
30.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.05 and its highest was $8.87 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Abeona Therapeutics’s market cap is $237.35M.
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 10 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Nov 14, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.392 by -$0.238.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 43,471,030 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.392. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Currently, no hedge funds are holding shares in ABEO
---
Abeona Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (177.28% Upside)
$15.50 (177.28% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 386.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.08%
12-Months-Change
Fundamentals
Return on Equity
-209.50%
Trailing 12-Months
Asset Growth
82.47%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. The company operates in the biotechnology and pharmaceutical sectors, emphasizing innovative treatments for conditions with significant unmet medical needs. Abeona's core product candidates target disorders such as recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo syndrome, utilizing its proprietary AIM AAV vector platform and CRISPR/Cas9 technology.
---
ABEO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated significant progress towards the approval and commercialization of pz-cel, with strategic steps in place for launch and financial stability. However, there remain challenges related to manufacturing capacity and ongoing financial losses.Read More>---
ABEO Stock 12 Month Forecast
Average Price Target
$15.50
▲(177.28% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
uniQure
―
Brainstorm Cell Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering ABEO
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+8.03%
reiterated a buy rating 7 months ago
Copying Dae Gon Ha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +8.03% per trade.
---